MetaCap

Grace Therapeutics Inc. (GRCE)

NASDAQ: GRCEHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.71-0.01 (-0.58%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

GRCE stock chart

Technical analysis

Key statistics

All statistics
Market cap
$35.97M
EPS (TTM)
-$1.16
52-week range
1.64 – 5.18
Day range
1.68 – 1.82
Volume / Avg
153.91K / 119.27K
Beta
—

52-week range

$1.64$5.18

GRCE stock today

Grace Therapeutics (GRCE) closed at $1.71 on Nov 20, down 0.58% (-$0.01), versus the S&P 500's 3.70% decline. Shares are 67.0% below their 52-week high of $5.18, set on Apr 2, 2026 and 4.3% above the 52-week low of $1.64, near the bottom of the past year's range. GRCE is down 50.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 46.4%.

Grace Therapeutics has posted a net loss over the last twelve months (EPS of -$1.16), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Grace Therapeutics

Company profile

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Prashant Kohli
Headquarters
Princeton, NJ
Employees
5

Financial highlights

Full financials

Grace Therapeutics reported a net loss of $7.8 million, compared with a loss of $9.6 million a year earlier. Diluted earnings per share came in at -$0.47.

Grace Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2026FY 2025FY 2024FY 2023FY 2022
Revenue————$100.00M
Growth————+50920.41%
Net income$-7.79M$-9.57M$-12.85M$-42.43M$-9.82M
EPS (diluted)$-0.47$-0.79$-1.35$-5.71$-0.27

Analyst forecast

Forecast

Consensus (2 analysts)

none

Avg. price target

$5.87+243.27%

  • Strong buy 0
  • Buy 2
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $3.90High $7.83

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.11 vs —

GRCE news

All GRCE news

Grace Therapeutics peers

Health Care sector
GRCE peer companies
CompanyPrice% ChgMarket capCompare
PLRXPliant Therapeutics Inc.0.5951-4.02%$36.89Mvs GRCE
SDEVStablecoin Development Corporation0.50-10.30%$36.90Mvs GRCE
CNTBConnect Biopharma Holdings Limited0.59-6.08%$38.05Mvs GRCE
CUECue Biopharma Inc.4.15-7.78%$34.69Mvs GRCE
DWTXDogwood Therapeutics Inc.1.04-2.36%$39.57Mvs GRCE
VERUVeru Inc.1.94-8.06%$33.08Mvs GRCE
ATNMActinium Pharmaceuticals Inc. (Delaware)1.05-1.87%$33.01Mvs GRCE
HYFTMindWalk Holdings Corp.0.6844-14.27%$32.56Mvs GRCE

Indexes, lists and sector

Grace Therapeutics stock FAQ

What is Grace Therapeutics's stock price today?

GRCE last traded at $1.71 as of Nov 20, 4:00 PM EST, down 0.58% on the day. Prices are delayed at least 15 minutes.

Does Grace Therapeutics pay a dividend?

No. Grace Therapeutics does not currently pay a regular cash dividend.

Who is Grace Therapeutics's CEO?

Mr. Prashant Kohli is the chief executive officer of Grace Therapeutics Inc., which has about 5 employees.

Has GRCE ever split its stock?

Yes. The most recent GRCE stock split was a 1-for-6 split on Jul 10, 2023, one of 3 splits on record.

What is the GRCE 52-week high?

The 52-week high for GRCE is $5.18 and the 52-week low is $1.64. The stock is currently 67.0% below its high.

Compare GRCE